Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.
Omeros announces positive results from a pivotal narsoplimab trial in TA-TMA, showing significant survival benefits and advancing regulatory submissions.
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million.
